RecruitingPhase 1NCT07015697

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Sponsor

Daiichi Sankyo

Enrollment

76 participants

Start Date

Jul 17, 2025

Study Type

INTERVENTIONAL

Conditions

Recurrent or Metastatic Solid Tumors

Summary

This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Trastuzumab Deruxtecan for people with recurrent or metastatic solid tumors. The study is currently recruiting participants at 26 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTrastuzumab Deruxtecan

Dose Escalation Part: Trastuzumab Deruxtecan will be administered at escalating doses to determine the RDE. Expansion Part: Trastuzumab Deruxtecan will be administered at RDE.

Locations(31)

Research Site

Newport Beach, California, United States

Research Site

Atlanta, Georgia, United States

Research Site

Las Vegas, Nevada, United States

Research Site

Charlotte, North Carolina, United States

Research Site

Maumee, Ohio, United States

Research Site

Nashville, Tennessee, United States

Research Site

Asa Sul, Brazil

Research Site

Goiás, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Santo André, Brazil

Research Site

São Paulo, Brazil

Research Site Saint

Herblain, France

Research Site

Rennes, France

Research Site

Chiba, Japan

Research Site

Kanagawa, Japan

Research Site

Tokyo, Japan

Research Site

Tokyo, Japan

Research Site

Tokyo, Japan

Research Site

Seongnam-si, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

Madrid, Spain

Research Site

Seville, Spain

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan City, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07015697

Related Trials

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064119 locations